

[Request Information](#)[Permalink](#)

METHOD FOR DETECTING AND TREATING NASAL AND LUNG DYSBIOSIS PATIENTS WITH MICROORGANISMS

Tech ID: 28797 / UC Case 2017-187-0

CONTACT

Hailey Zhang

hailey.zhang@ucsf.edu

tel: .

**OTHER INFORMATION****KEYWORDS**

Microorganisms, Nasal

dysbiosis, Lung dysbiosis,

Respiratory system, Immune

dysfunction, Inflammatory

disease

CATEGORIZED AS

- ▶ [Biotechnology](#)
- ▶ [Health](#)
- ▶ [Medical](#)
- ▶ [Diagnostics](#)
- ▶ [Disease: Respiratory and Pulmonary System](#)
- ▶ [Therapeutics](#)

RELATED CASES

2017-187-0

INVENTION NOVELTY

This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.

VALUE PROPOSITION

The respiratory system hosts a large and diverse number of microorganisms, which function as a unit and are associated with human health and disease states. Distinct compositions of microbiota are associated with the development of distinct immune dysfunctions, including inflammatory bowel disease, pediatric asthma, acute pneumonia and chronic rhinosinusitis, and are also associated with significant differences in clinical outcomes.

Currently, microbiota are not considered during diagnosis of lung or nasal dysbiosis. This invention identifies microbial endotypes that would benefit from differentiated therapy.

This novel invention provides the following benefits:

- Rapid** access to testing results
- Relatively **inexpensive** testing
- Opportunity to implement **precision medicine**

TECHNOLOGY DESCRIPTION

Researchers at the University of California, San Francisco have demonstrated that distinct populations of microbiota in patients with acute infection or chronic inflammatory disease are associated with distinct immune dysfunction and differences in clinical response. They have developed a method to obtain a microorganism sample and probe the microorganism population to identify diversity and plurality of microbiota.

APPLICATION

- Identify distinct populations of microbiota in patients
- Develop tailored treatment based on microbiota composition

LOOKING FOR PARTNERS

To develop and commercialize this technology to stratify and treat nasal and lung dysbiosis patients

STAGE OF DEVELOPMENT

Preclinical

DATA AVAILABILITY

Under NDA/CDA

[Inventors Profile](#)

PATENT STATUS

Patent Pending

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,
San Francisco, CA 94158

CONTACT

Tel:

innovation@ucsf.edu

<https://innovation.ucsf.edu>

Fax:

CONNECT

 Follow  Connect

© 2017 - 2020, The Regents of the University
of California

[Terms of use](#) [Privacy Notice](#)